Routine Sample Size for a Retest Procedure

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-11-02-2003
Volume 27
Issue 11

This article discusses a straightforward approach that scientists may use to descide how many nonsuspect restest results are required to provide sufficient evidence to overcome an initial suspect result.

External Link - article-75176.pdf

Articles in this issue
FDA Will Drive Changes for Contract Business
In the Spotlight--December
Novemember 2003
FDA Seeks Risk-Based Inspection Program
Routine Sample Size for a Retest Procedure
November 2003
Aseptic Processing Guidelines and Innovative Engineering Boost Appeal of Barrier Isolators
Clearing Regulatory Hurdles
Improving Protein Capture for Transgenic Drug Processing
Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

ACG to Showcase Sustainability Innovations at Pharmapack Europe 2025

Susan Haigney
January 21st 2025
Article

The company will be featuring its sustainable packaging solutions at the event in Paris on Jan. 22–23, 2025.

Drug Solutions Podcast: Realizing AI’s Potential

Drug Solutions Podcast: Realizing AI’s Potential

Felicity Thomas
December 20th 2024
Podcast

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Samsung Biologics Scores Major Manufacturing Deal Worth Over $1.4 Billion with European Pharma Company

Feliza Mirasol
January 17th 2025
Article

Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.

Drug Solutions Podcast: Dosage Forms: Roundtable on Oral Solid Dosage Trends

Drug Solutions Podcast: Dosage Forms: Roundtable on Oral Solid Dosage Trends

Patrick Lavery
October 30th 2024
Podcast

In this podcast episode, we discuss trends in dosage forms, specifically oral solid dosage, as viewed by five industry experts who recently exhibited at CPHI Milan.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Pharmapack Reports on Key Trends for 2025

Feliza Mirasol
January 16th 2025
Article

Pharmapack identifies biologic approvals, drug delivery advancements, GLP-1 generics, and the return of funding flow as drivers for a record year in 2025.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

Lyndra, Thermo Fisher to Partner on R&D for Long-Acting Oral Therapies

Patrick Lavery
January 15th 2025
Article

The collaboration will leverage Thermo Fisher’s Accelerator Drug Development stable of solutions, which was launched in the fall of 2024.